Axonis Therapeutics
Boston, US · 10 known investors
Axonis Therapeutics develops medicines targeting KCC2 to restore inhibition in the brain, with a focus on treating neurological disorders including epilepsy and pain. The company translates discoveries from Boston Children's Hospital, Harvard, and Laval University into first-in-class and best-in-class treatments.
Investors · 10
Civilization Ventures Management, LlcTiburon · $1M – $10M
Hatteras Venture PartnersResearch Triangle · $500K – $4M
Iaso VenturesCambridge
Lumira VenturesToronto · $1M – $10M
Pathway BioventuresChicago
Solasta VenturesBoston
Tachyon VenturesLos Angeles
venBio PartnersSan Francisco
BoxOne VenturesreportedMontréal · $500K – $500K
Sofinnova VenturesreportedMenlo Park · $100K – $15M
In the news
- Business Post (@businessposthq) on Xx.com · 2024
- Axonis Therapeutics bags $115m for neuromedicine developmentsiliconrepublic.com · 2024
- Axonis Therapeutics gets $115 million to treat paincen.acs.org · 2024
- With $115 million, biotech startup Axonis Therapeutics pivots to burgeoning pain fieldstatnews.com · 2024
- Axonis Therapeutics Raises $115M in Series A Financing to Advance Novel Neuromedicines | Venture Capitalventurecapital.com · 2024
- Axonis Therapeutics Raises $115M in Series A Financingfinsmes.com · 2024